Changeflow GovPing Healthcare & Life Sciences Gen-Probe Patent, Magnetic Bead Lysis in Fluidi...
Routine Notice Added Final

Gen-Probe Patent, Magnetic Bead Lysis in Fluidic Cartridge

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

Gen-Probe Incorporated filed US Patent Application US20260110020A1 on December 18, 2025, describing a fluidic cartridge system for lysing cells using magnetic agitation of non-magnetic beads combined with a magnetic element. The invention incorporates an internal control reagent deposited on beads and the magnetic element to validate assay results and cell lysis effectiveness. The magnetic field causes controlled movement of the magnetic element and non-magnetic beads, which mechanically lyses cells and releases nucleic acids, while the internal control distributes throughout the fluid sample. Inventors Byron J. Knight, Norbert D. Hagen, and David Opalsky are named on the application.

“The magnetic element is exposed to a magnetic field, thereby causing movement of the magnetic element, which causes movement of the non-magnetic beads.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.

What changed

Gen-Probe Incorporated filed US Patent Application US20260110020A1 with the USPTO on December 18, 2025, published April 23, 2026, covering a method and system for lysing cells within a fluidic cartridge using magnetic agitation. The application claims a cartridge containing non-magnetic beads and a magnetic element with an internal control reagent, where exposure to a magnetic field causes bead movement sufficient to lyse cells and release nucleic acids.

Affected parties include diagnostic manufacturers, molecular biology companies, and laboratories developing or using automated nucleic acid extraction systems. While patent applications do not create immediate compliance obligations, competitors in the molecular diagnostics or automated sample-processing space should review this filing to assess potential freedom-to-operate implications for their own cartridge-based lysis technologies. The CPC classifications (C12Q 1/6844, C12N 15/1006, C12Q 1/6806) indicate relevance to nucleic acid testing and sample preparation methods.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

LYSIS IN A FLUIDIC CARTRIDGE BY MAGNETIC AGITATION OF LYSIS ELEMENTS AND WITH INTERNAL CONTROL

Application US20260110020A1 Kind: A1 Apr 23, 2026

Assignee

Gen-Probe Incorporated

Inventors

Byron J. KNIGHT, Norbert D. HAGEN, David OPALSKY

Abstract

A fluid sample is dispensed into a sample chamber of a fluidic cartridge, the sample chamber containing non-magnetic beads and a magnetic element. A portion of the non-magnetic beads and magnetic element have an internal control reagent containing an internal control deposited thereon for validating an assay result and/or to validate the effectiveness of a cell lysis procedure. The magnetic element is exposed to a magnetic field, thereby causing movement of the magnetic element, which causes movement of the non-magnetic beads. Movement of the non-magnetic beads causes cells contained within the fluid sample to lyse and release nucleic acids. The internal control reagent dissolves in the presence of the fluid sample, thereby releasing the internal control into the fluid sample, and the movement of the magnetic element and the non-magnetic beads causes the internal control to be distributed within the fluid sample.

CPC Classifications

C12Q 1/6844 C12N 15/1006 C12Q 1/6806

Filing Date

2025-12-18

Application No.

19424814

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Medical device makers Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent filing IP management Diagnostic technology
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Medical Devices Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!